A Phase 2a combined open-label and double-blind, placebo-controlled crossover study assessing the effectiveness, safety, and tolerability of oral Fasudil in subjects with dementia and wandering behaviours of elopement and/or getting lost

Occurring Dates
to
Participant Duration
20 study visits over a period of approximately 30 weeks
State of study
South Australia
Western Australia
Victoria
Overview

Fasudil, a Rho kinase inhibitor, is believed to reduce wandering behaviors of elopement and getting lost by improving spatial memory and navigation through improvements in hippocampal blood flow. Fasudil is non-sedating.

The aim of the study is to assess the effectiveness of oral fasudil in reducing wandering behaviors of elopement and/or getting lost in subjects with dementia. In addition, effects on wandering behaviors of excess movement and pacing, cognition, memory, neuropsychiatric symptomatology, caregiver/nursing staff burden, and the safety and tolerability of fasudil treatment will be assessed.

The study population will consist of subjects with dementia and wandering behaviors of elopement and/or getting lost. While it is anticipated that most participants will be residing at home (with caregiver support), subjects may live in another setting such as a group home, an assisted living unit, or in a long-term care facility, provided that a caregiver, formal or informal, has sufficient contact with the subject to permit accurate completion of the necessary assessments.

Further information

For further information or to participate in this study, please contact Cheryl MacFarlane on (08) 6317 9472 or at [email protected].

This project has been approved by the St Vincent’s Human Research Ethics Committee (Reference: HREC 308/20).

Study Address
North East Health
Wangaratta, Victoria
Email: [email protected]

Barwon Geriatrics
Geelong, Victoria
Email: [email protected]

Goulburn Valley Health
Shepparton, Victoria
Email: [email protected]

Modbury Hospital
Modbury, South Australia
Email: [email protected]

Neurodegenerative Disorders Research
West Perth, Western Australia
Email: [email protected]
Full Name
Cheryl MacFarlane
Institute
Neurodegenerative Disorders Research Pty Ltd
Phone Number
(08) 6317 9472